Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

PCSA

Phase 2

NGC- Capecitabine (PCS6422)

CRC (Colorectal Cancer), Pancreatic, Breast & solid tumor cancers

mid-2025

Presented new Phase 1b data at AACR '24. 6/11/24- Efficacy results from Ph1b dose-esc. in GI cancer. 10/2/24- First patient dosed in metastatic breast cancer trial with interim data in mid-2025.

Data readout

AMLX

Phase 3

AMX0035

Progressive supranuclear palsy (PSP)

Mid-2025

ORION trial. 10/19/23 - Trial design presentation at Neuro '23. 12/22/23- First patient dosed. Interim analysis in Mid 2025. Topline results in 2025 or 2026.

Data readout

BCAB

Phase 1/2

CAB-EpCAM x CAB-CD3 TCE (BA3182)

Adenocarcinoma

mid-2025

11/7/24- Dose escalation ongoing with Ph1 data readout around mid-2025.

Data Readout

ATXS

Phase 2

STAR-0215

Hereditary Angioedema

Mid-2025

ALPHA-SOLAR. 8/30/24- Present updated results at Bradykinin Symposium on September 6, 2024. Initial safety and efficacy data from Q3M and Q6M in mid-2025.

Data readout

LPTX

Phase 2

DKN-01 (Bevacizumab & Chemotherapy)

Colorectal Cancer (CRC)

2025

DeFianCe study. 3/18/24- Presented updated data from Part A at ASCO GC '24. 9/30/24 Complete Part B enrollment with data in mid-2025. 1/28/25- Initial data from Part B reported. Preparing for Ph3 study in 2L CRC patients. Report additional data as it matures in 2025.

Additional data readout

LSTA

Phase 2a

LSTA1 + Standard of care

CCA (Cholangiocarcinoma)

mid-2025

BOLSTER trial. 7/16/24- Completed enrollment in 1L CCA cohort with top-line data in mid-2025. 9/17/24- First patient dosed in the 2L cohort. 11/12/24- 2L enrollment complete in H1 2025.

Data Readout

GNLX

Phase 2

Olvi-Vec (Olvimulogene nanivacirepvec)

Non-small cell lung cancer (recurrent/platinum-ICI failure)

Mid-2025

VIRO-25 trial. 10/22/24- First patient dosed in Ph2. Interim readout in mid-2025.

Data readout

ATAI

Phase 2b

BPL-003 (Intranasal 5-MeO-DMT)

TRD (Treatment-resistant depression)

mid-2025

w/ Beckley Psytech. 3/27/24- Reported positive initial Ph2a data. 4/24/24- 1st patient dosed in Part 2 of Ph2a study. Q4 2024- Completed enrollment for Ph2b trial; topline results in mid-2025.

Data readout

LSTA

Phase 2b

Certepetide (LSTA1)

Non-Resectable Pancreatic Ductal Adenocarcinoma (PDAC)

Mid-2025

ASCEND trial. 4/18/23 -First patient treated. 12/12/23- Enrollment complete. 11/12/24- Interim analysis to be presented at ASCO-GCS in January 2025. Data from Cohort B in mid-2025, final analysis of both cohorts to follow after. 1/22/25- Encouraging Cohort A data reported.

Additional Data readout

CMRX

PDUFA

Dordaviprone (ONC201)

recurrent H3 K27M-mutant diffuse glioma

August 18, 2025

ACTION study. 12/30/24- Submitted NDA. 2/18/25- NDA accepted & priority review with PDUFA date of August 18, 2025. 3/5/25- Company acquired by JAZZ, transaction to close in Q2 2025.

Approval decision

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20